BIT
ACAD icon

BlackRock Institutional Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

BlackRock Institutional Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$69.1M Buy
2,397,396
+86,715
+4% +$2.29M 0.01% 1139
2016
Q3 		$73.5M Buy
2,310,681
+116,594
+5% +$3.95M 0.01% 1053
2016
Q2 		$71.2M Buy
2,194,087
+101,128
+5% +$3.38M 0.01% 1034
2016
Q1 		$58.5M Buy
2,092,959
+114,358
+6% +$2.49M 0.01% 1123
2015
Q4 		$70.5M Buy
1,978,601
+86,501
+5% +$3.05M 0.01% 1033
2015
Q3 		$62.6M Sell
1,892,100
-69,342
-4% -$2.89M 0.01% 1110
2015
Q2 		$82.1M Sell
1,961,442
-462,936
-19% -$17.9M 0.01% 1016
2015
Q1 		$79M Buy
2,424,378
+363,768
+18% +$12.5M 0.01% 1060
2014
Q4 		$65.4M Sell
2,060,610
-57,578
-3% -$1.63M 0.01% 1118
2014
Q3 		$52.4M Sell
2,118,188
-126,020
-6% -$2.95M 0.01% 1222
2014
Q2 		$50.7M Buy
2,244,208
+19,033
+0.9% +$397K 0.01% 1315
2014
Q1 		$54.1M Buy
2,225,175
+193,854
+10% +$4.9M 0.01% 1226
2013
Q4 		$50.8M Buy
2,031,321
+33,997
+2% +$802K 0.01% 1241
2013
Q3 		$54.9M Buy
1,997,324
+80,860
+4% +$1.69M 0.01% 1141
2013
Q2 		$34.8M Buy
+1,916,464
New +$26.4M 0.01% 1391

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock Institutional Trust's ACAD Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Acadia Pharmaceuticals (ACAD) stake by 3.8% in Q4 2016, buying an estimated $2.29M and bringing the position to 2,397,396 shares worth $69.1M. The position accounts for 0.01% of the portfolio, ranked #1139.

BlackRock Institutional Trust first reported a position in ACAD in Q2 2013 and has held it in 15 quarters since. The position peaked at $82.1M in Q2 2015. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • BlackRock Institutional Trust held 2,397,396 shares of Acadia Pharmaceuticals worth $69.1M as of Q4 2016.
  • BlackRock Institutional Trust bought 86,715 Acadia Pharmaceuticals shares in Q4 2016, an estimated $2.29M.
  • Acadia Pharmaceuticals made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1139 holding.
  • BlackRock Institutional Trust first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Acadia Pharmaceuticals position peaked at $82.1M in Q2 2015.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.